Aller au contenu principal
Accès ouvert déclaré 2024 article

Is Progesterone Receptor a Neglected Feature in Breast Cancer? A Retrospective Study Analysing the Clinicopathological Characteristics of Breast Cancer Based on Progesterone Receptor Status

8Citations signalées, ce qui n’est pas une note de qualité
4Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : pt. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

PURPOSE: The aim of this study is to analyse PR independently and its relationship with demographic and clinicopathological information. INTRODUCTION: Steroid hormones, particularly estrogen and progesterone, play a crucial role in breast cancer (BC) etiology. Research attention has focused mainly on estrogen while the progesterone impact on breast cancer has yet to be fully uncover. Hormone receptors, including those for estrogen and progesterone, are crucial in BC molecular classification, shaping prognosis and treatment strategies. Beyond its metabolic effects, progesterone and its receptor (PR) have significant clinical implications, impacting clinical outcomes. MATERIALS AND METHODS: The study comprised 2223 women who were diagnosed with BC at the Comprehensive Cancer Centre in Portugal (IPO-Porto) between 2012 and 2016. Variables, including age at diagnosis, body mass index (BMI), laterality, topographic localization, histological type, differentiation grade, tumor stage, estrogen receptor (ER) and Human Epidermal growth factor Receptor 2 (HER2) expression, were stratified according to the expression of Progesterone Receptor. Statistical analysis included Pearson's Chi-squared test, binary and multinomial regression, and Cox proportional hazard model. Statistical significance was set for P < .05. RESULTS: The results reveal a statistical association between PR and BMI, histological type, differentiation grade, tumour stage, ER and HER2. Progesterone receptor negativity is associated with adverse clinical outcomes, including advanced tumor stages, and diminished overall survival. CONCLUSION: Further research is needed to elucidate the precise contributions of progesterone to breast cancer progression and to optimize therapeutic approaches for improved patient outcomes.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Is Progesterone Receptor a Neglected Feature in Breast Cancer? A Retrospective Study Analysing the Clinicopathological Characteristics of Breast Cancer Based on Progesterone Receptor Status
Date Crossref
01/06/2025
Éditeur
Elsevier BV
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Estrogen and related hormone effectsCancer Risks and FactorsBreast Cancer Treatment Studies

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.